Pharmigene, Inc. (TPEX:7595)
Taiwan · Delayed Price · Currency is TWD 10.50
0.00 (0.00%)
Feb 11, 2026, 2:39 PM CST
Pharmigene Revenue
Pharmigene had revenue of 80.68M TWD in the half year ending June 30, 2025, with 50.57% growth. This brings the company's revenue in the last twelve months to 149.25M, up 17.45% year-over-year. In the year 2024, Pharmigene had annual revenue of 116.53M, down -12.19%.
Revenue (ttm)
149.25M
Revenue Growth
+17.45%
P/S Ratio
3.55
Revenue / Employee
n/a
Employees
42
Market Cap
529.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 116.53M | -16.17M | -12.19% |
| Dec 31, 2023 | 132.71M | -1.09M | -0.82% |
| Dec 31, 2022 | 133.80M | 4.45M | 3.44% |
| Dec 31, 2021 | 129.35M | 28.00M | 27.63% |
| Dec 31, 2020 | 101.35M | 36.07M | 55.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Health & Life | 441.84M |
| Welgene Biotech | 365.75M |
| EBM Technologies | 348.42M |
| Taiwan Advanced Nanotech | 172.11M |
| UniPharma | 90.79M |
| Vectorite Biomedical | 67.90M |